» Articles » PMID: 32806657

COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions

Overview
Journal Microorganisms
Specialty Microbiology
Date 2020 Aug 19
PMID 32806657
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Until less than two decades ago, all known human coronaviruses (CoV) caused diseases so mild that they did not stimulate further advanced CoV research. In 2002 and following years, the scenario changed dramatically with the advent of the new more pathogenic CoVs, including Severe Acute Respiratory Syndome (SARS-CoV-1), Middle Eastern respiratory syndrome (MERS)-CoV, and the new zoonotic SARS-CoV-2, likely originated from bat species and responsible for the present coronavirus disease (COVID-19), which to date has caused 15,581,007 confirmed cases and 635,173 deaths in 208 countries, including Italy. SARS-CoV-2 transmission is mainly airborne via droplets generated by symptomatic patients, and possibly asymptomatic individuals during incubation of the disease, although for the latter, there are no certain data yet. However, research on asymptomatic viral infection is currently ongoing worldwide to elucidate the real prevalence and mortality of the disease. From a clinical point of view, COVID-19 would be defined as "COVID Planet " because it presents as a multifaceted disease, due to the large number of organs and tissues infected by the virus. Overall, based on the available published data, 80.9% of patients infected by SARS-CoV-2 develop a mild disease/infection, 13.8% severe pneumonia, 4.7% respiratory failure, septic shock, or multi-organ failure, and 3% of these cases are fatal, but mortality parameter is highly variable in different countries. Clinically, SARS-CoV-2 causes severe primary interstitial viral pneumonia and a "cytokine storm syndrome", characterized by a severe and fatal uncontrolled systemic inflammatory response triggered by the activation of interleukin 6 (IL-6) with development of endothelitis and generalized thrombosis that can lead to organ failure and death. Risk factors include advanced age and comorbidities including hypertension, diabetes, and cardiovascular disease. Virus entry occurs via binding the angiotensin-converting enzyme 2 (ACE2) receptor present in almost all tissues and organs through the Spike (S) protein. Currently, SARS-CoV-2 infection is prevented by the use of masks, social distancing, and improved hand hygiene measures. This review summarizes the current knowledge on the main biological and clinical features of the SARS-CoV-2 pandemic, also focusing on the principal measures taken in some Italian regions to face the emergency and on the most important treatments used to manage the COVID-19 pandemic.

Citing Articles

Markers of liver function as potential prognostic indicators of SARS-CoV-2 infection: A retrospective analysis during the first and second waves of COVID-19 pandemic.

Esposito L, Guarino M, Perna B, Ciccarone A, Cesaro A, Manza F Infez Med. 2023; 31(2):209-214.

PMID: 37283636 PMC: 10241392. DOI: 10.53854/liim-3102-9.


S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review.

Nejat R, Torshizi M, Najafi D Vaccines (Basel). 2023; 11(2).

PMID: 36851081 PMC: 9968219. DOI: 10.3390/vaccines11020204.


Impact of the COVID-19 Pandemic on Inappropriate Use of the Emergency Department.

Fernandez Chavez A, Aranaz-Andres J, Roncal-Redin M, Roldan Moll F, Estevez Rueda M, Alva Garcia P Microorganisms. 2023; 11(2).

PMID: 36838388 PMC: 9966034. DOI: 10.3390/microorganisms11020423.


Airway Management in Adult Intensive Care Units: A Survey of Two Regions in China.

Zhang S, Lin J, Diao X, Shi W, Huang L Biomed Res Int. 2022; 2022:4653494.

PMID: 36452062 PMC: 9705077. DOI: 10.1155/2022/4653494.


Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2.

Wei X, Rong N, Liu J Front Immunol. 2022; 13:993754.

PMID: 36189203 PMC: 9523127. DOI: 10.3389/fimmu.2022.993754.


References
1.
Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M . The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020; 92(4):455-459. PMC: 7166400. DOI: 10.1002/jmv.25688. View

2.
Sullivan H, Roback J . Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfus Med Rev. 2020; 34(3):145-150. PMC: 7179481. DOI: 10.1016/j.tmrv.2020.04.001. View

3.
Holshue M, DeBolt C, Lindquist S, Lofy K, Wiesman J, Bruce H . First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020; 382(10):929-936. PMC: 7092802. DOI: 10.1056/NEJMoa2001191. View

4.
Wan Y, Shang J, Graham R, Baric R, Li F . Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol. 2020; 94(7). PMC: 7081895. DOI: 10.1128/JVI.00127-20. View

5.
Alnaeem A, Kasem S, Qasim I, Al-Doweriej A, Refaat M, Al-Shabebi A . The dipeptidyl peptidase-4 expression in some MERS-CoV naturally infected dromedary camels in Saudi Arabia 2018-2019. Virusdisease. 2020; 31(2):200-203. PMC: 7201121. DOI: 10.1007/s13337-020-00586-y. View